Tradestie Institutional Equity Comparison Engine

BEAG vs ABUS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while BEAG counters with relative strength in Momentum & Technical. Fundamentally, BEAG trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, BEAG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABUS
BEAG N/M vs ABUS 10.2x Fwd P/E
Growth & Margin Winner ABUS
Op Margin 0.0% vs 80.1% ยท YoY +0.0% vs -43.5%
Momentum & Technical Winner BEAG
1Y -2.4% vs -5.8% ยท 52W Pos 47% vs 27%
Options & Structure Winner ABUS
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (18th %ile IV)
BEAG NASDAQ
Bold Eagle Acquisition Corp. Class A Ordinary Shares
Blank Checks
$10.62
+0.0% 1D
Market Cap $169.1M
1M Return +1.05%
1Y Return -2.39%
Forward P/E N/M
Unified AI Score
52.7 / 100 HOLD
Tech 54.0 Fund 52.0 Flow 50.0 Mom 50.0
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.02
-1.23% 1D
Market Cap $623.9M
1M Return -4.51%
1Y Return -5.85%
Forward P/E 10.2x
Unified AI Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 68.0 Mom 53.7

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BEAG -2.39% ABUS -5.85% Spread: +6.8 pp (BEAG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BEAG TTM Op. Margin: 0.0% ABUS TTM Op. Margin: 80.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BEAG vs ABUS. Trailing 12-month operating profitability (BEAG 0.0% vs ABUS 80.1%) and valuation multiples (BEAG N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BEAG (4) vs ABUS (6)
Institutional Metric BEAG ABUS Criterion Row Winner
Market Capitalization Scale $169.1M $623.9M Larger Scale ABUS
Trailing P/E Ratio Valuation 59.0x 3.6x Lower Multiple ABUS
Forward P/E Ratio Valuation N/M 10.2x Lower Multiple ABUS
Revenue Growth (YoY) Growth +0.0% -43.5% Higher Growth BEAG
Operating Margin (TTM) Profitability 0.0% 80.1% Higher Margin ABUS
Net Profit Margin Profitability 0.0% 121.2% Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency 0.0% 269.6% Higher ROE ABUS
52-Week Range Position Momentum 47% ($10โ€“$11) 27% ($4โ€“$5) Stronger Trend BEAG
Beta / 30D Volatility Risk Regime -0.01ฮฒ ยท 8% Vol 1.04ฮฒ ยท 48% Vol Lower Realized Risk BEAG
Unified Institutional Score Composite Signal 52.7 / 100 (HOLD) 43.4 / 100 (HOLD) Higher Composite BEAG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BEAG vs ABUS Buy Guide
BEAG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BEAG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABUS CONSOLIDATION
96d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BEAG nor ABUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.